Meeker David P

RYTM CEO Meeker sold 43,620 shares for $2,837,333.35 (blended $65.05) on 2025-06-03; -17.8% of holdings.

David P Meeker, President and CEO of Rhythm Pharmaceuticals, executed 2 separate sales totaling 43,620 (43.6K shares) for $2,837,333.35 at a blended average price of $65.05, reducing his stake by 17.8% from 245,445 shares to 201,825 shares post-transaction. The timing is noteworthy: the stock has risen 5.5% over the prior 30 days and 30.3% over the prior 90 days, trading within 1.7% of its 52-week high of $67.33, suggesting the sale occurred at elevated valuation. Rhythm remains unprofitable (net income of $-49,498,000.00 on revenue of $32,704,000.00 in the latest quarter) despite strong annual revenue growth of 68.1%, a profile where insider sales near 52-week highs warrant monitoring. Meeker's prior 2 sales at RYTM on 2025-02-19 and 2024-03-19 were not well-timed; the stock subsequently gained 11.6% and 5.0% respectively over 90 days following those sales.

RYTM CEO Meeker sold 9,896 shares at $57.22 (2/19/2025); stock at $58.00, down 13.9% from high.

David P Meeker, the CEO of Rhythm Pharmaceuticals, sold 9,896 shares at $57.22 on February 19, 2025, reducing his holdings by 4.7% to 201.3K shares. The sale occurred near current trading levels ($58.00), though the stock has declined 13.9% from its 52-week high of $67.33 and remains essentially flat over the past 90 days (-1.7%). Meeker's cross-ticker track record shows a 0.00% well-timed rate on prior sells, and his single prior RYTM transaction (a sell on 2024-03-19) was also poorly timed, with the stock rising 5.0% over the subsequent 90 days. The company reported strong annual revenue growth of 227.6%, but remains unprofitable with a latest-quarter net income of -$43.6M against $33.3M in revenue, suggesting the executive sale occurred in a context of ongoing losses and elevated valuation pressure relative to fundamentals.